|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.3000 - 0.7000|
|52 Week Range||0.0123 - 1.2000|
|Beta (5Y Monthly)||7.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MIAMI, FL / ACCESSWIRE / March 27, 2020 / Ehave, Inc., (OTC PINK:EHVVF) (the "Company"), announced today that Dr. Mark Braunstein, DO, ABPN has been appointed to its Medical Advisory Board as its Chief Psychedelic Officer. Dr. Braunstein will join other members of the Medical Advisory Board evaluating various technologies, acquisitions, investments, joint ventures, and all other business related to psychedelics.
Seattle, Washington--(Newsfile Corp. - February 28, 2020) - CFN Media (OTCQB: CNFN), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article discussing the next frontier in drug research.A big factor in the recent rise of cannabis legalization is the emergence of legitimate scientific research into the potential health benefits of the plant's active ingredients, called cannabinoids. Medicines are often derived from naturally occurring compounds, ...
MIAMI, FL / ACCESSWIRE / February 14, 2020 / Ehave, Inc., (OTC PINK:EHVVF) a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today plans to utilize its mental health informatics platform to optimize patient care and health outcomes in conjunction with Psilocybin therapy for mental health. Ehave plans to advance Psilocybin therapy research and commercialization through its wholly-owned subsidiary, Mycotopia Therapy.
Ehave, Inc. to Present Ehave Dashboard at the 2020 HIMSS Global Health Conference & Exhibition, March 9-13, 2020 in Orlando MIAMI, FL / ACCESSWIRE / February 6, 2020 / Ehave, Inc., (OTC PINK:EHVVF) (the ...
MIAMI, FL / ACCESSWIRE / February 5, 2020 / Ehave, Inc., (OTC PINK:EHVVF) (the "Company"), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the appointment of Russell Schachar, MD, FRCP(C) as Chief Medical Officer. Dr. Schachar is a practicing child and adolescent psychiatrist, Professor in the Department of Psychiatry at the University of Toronto, and Senior Scientist in the Research Institute at the Hospital for Sick Children in Toronto, Canada where he holds the TD Bank Chair in Child and Adolescent Psychiatry and heads a cognitive neurosciences laboratory which focuses on psychiatric disorders of childhood and adolescence.
Psychedeli-Tech prepares to lead in the commercialization of research into psychedelics for the treatment of anxiety, depression, and other mental illnesses. After decades of stigma, psychedelics are the next therapeutic frontier.
Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today that Alfred Farrington, II has joined the Company as acting Chief Information Officer, reporting to Chief Executive Officer Ben Kaplan, effective today. “We were impressed with Alfred’s proven track record aligning and integrating people, processes and technology," Mr. Kaplan said.
Ehave has been in the right industry, at the right time, and even though it had a great business plan and employed some very talented people, it did not necessarily equate to success Management executing a business plan is one, of the most critical components for success.
- Zyus to acquire assets relating to "Ehave Connect", the Company's health informatics platform. - New working capital intended to advance Ehave's development of digital assessments and therapeutic games for children with ADD/ADHD, ASD, and other mental health disorders. - Ehave will continue to evaluate merger and acquisition opportunities to maximize shareholder value.
TORONTO, ON / ACCESSWIRE / February 15, 2018 / Ehave, Inc. (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced ...